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ABSTRACT Lipid bodies, cytoplasmic inclusions that de-
velop in cells associated with inflammation, are inducible
structures that might participate in generating inflammatory
eicosanoids. Cis-unsaturated fatty acids (arachidonic and
oleic acids) rapidly induced lipid body formation in leuko-
cytes, and this lipid body induction was inhibited by aspirin
and nonsteroidal antiinflammatory drugs (NSAIDs). Several
findings indicated that the inhibitory effect of aspirin and
NSAIDs on lipid body formation was independent of cycloox-
ygenase (COX) inhibition. First, the non-COX inhibitor,
sodium salicylate, was as potent as aspirin in inhibiting lipid
body formation elicited by cis-fatty acids. Second, cis-fatty
acid-induced lipid body formation was not impaired in mac-
rophages from COX-1 or COX-2 genetically deficient mice.
Finally, NSAIDs inhibited arachidonic acid-induced lipid
body formation likewise in macrophages from wild-type and
COX-1- and COX-2-deficient mice. An enhanced capacity to
generate eicosanoids developed after 1 hr concordantly with
cis-fatty acid-induced lipid body formation. Arachidonic and
oleic acid-induced lipid body numbers correlated with the
enhanced levels of leukotrienes B4 and C4 and prostaglandin
E2 produced after submaximal calcium ionophore stimula-
tion. Aspirin and NSAIDs inhibited both induced lipid body
formation and the enhanced capacity for forming leukotrienes
as well as prostaglandins. Our studies indicate that lipid body
formation is an inducible early response in leukocytes that
correlates with enhanced eicosanoid synthesis. Aspirin and
NSAIDs, independent of COX inhibition, inhibit cis-fatty
acid-induced lipid body formation in leukocytes and in con-
cert inhibit the enhanced synthesis of leukotrienes and pros-
taglandins.
The capacity of cells to generate eicosanoid mediators of
inflammation may be enhanced by inducible mechanisms. One
such mechanism is the induction of expression of a specific
isoform of prostaglandin endoperoxide H synthase [cycloox-
ygenase (COX)], COX-2. Various cytokines and pro-
inflammatory stimuli elicit the de novo synthesis of COX-2
over two or more hours that leads to increased formation of
COX pathway-derived eicosanoids (1-4). Inducible mecha-
nisms that enhance eicosanoid production are attractive as
potential targets for selective antiinflammatory treatments.
Here we discuss a new mechanism for enhanced eicosanoid
synthesis based on the induction of lipid body in leukocytes.
Lipid bodies are lipid-rich cytoplasmic inclusions that char-
acteristically develop in vivo in cells associated with inflam-
mation; although neither the mechanisms of formation nor the
function of lipid bodies are fully understood, lipid bodies are
inducible structures. Lipid bodies are prominent in leukocytes
at sites of natural and experimental inflammation, including
leukocytes from joints of patients with inflammatory arthritis
(5-7), the airways of patients with acute respiratory distress
syndrome (8), and casein- or lipopolysaccharide-elicited
guinea pig peritoneal exudates (9). The formation of lipid
bodies is a regulated process that involves activation of intra-
cellular signaling pathways, including protein kinase C and
phospholipase C (10, 11). Inhibitors of mRNA and protein
synthesis inhibit lipid body formation, indicating that induction
of lipid body formation depends on the activation of specific
gene expression and new protein synthesis (11). The possibility
that lipid bodies have a role in the formation of eicosanoid
mediators of inflammation is suggested by their components.
Lipid bodies in several cell types contain COX and 5-lipoxy-
genase (refs. 12-14 and unpublished observations), both of
which use arachidonic acid (AA) to initiate synthesis of
inflammatory eicosanoids. In addition, stores ofAA have been
localized to lipid bodies in leukocytes, including polymorpho-
nuclear leukocytes (PMNs) and eosinophils (15, 16). More-
over, Bozzaetal. (11) have demonstrated, in platelet-activating
factor (PAF)-stimulated PMNs, a correlation between en-
hanced capacity for eicosanoid formation and levels of lipid
body induction.
Aspirin and other nonsteroidal antiinflammatory agents
(NSAIDs), widely used in treating inflammatory processes,
including arthritis (17, 18), are believed to act principally by
inhibition of COX thus blocking the initial step in prostaglan-
din synthesis (19). This mechanism may not, however, fully
account for the antiinflammatory effects of NSAIDs. Low
doses of aspirin and other NSAIDs are required for COX
inhibition in vitro and in vivo (19-21), whereas higher doses are
required for antirheumatic effects in vivo (17, 22). In addition,
sodium salicylate has minimal activity as a COX inhibitor (19),
but is as effective as aspirin for inhibiting inflammatory
manifestations of arthritis in humans and experimental models
(17, 22, 23). NSAIDs, by mechanisms other than COX inhi-
bition, also inhibit PMN activation, including the synthesis of
leukotrienes, eicosanoids formed by a lipoxygenase, and not a
COX, pathway (24-26). Thus, there is evidence to suggest that
the antiinflammatory effects of aspirin-like drugs are not
solely attributable to COX inhibition. Correlation of lipid body
formation with inflammatory responses led us to investigate
whether inhibition of lipid body formation could be a mech-
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anism for some of the antiinflammatory effects of aspirin and
NSAIDs.
MATERIALS AND METHODS
Materials. Aspirin, indomethacin, piroxicam, salicylic acid
(sodium salt), oleic acid (OA), AA (Sigma), 14C-AA (1.5-2.2
GBq/mmol; DuPont/NEN), A23187 (Calbiochem), and NS-
398 (Biomol, Plymouth Meeting, PA) were obtained as noted.
Human and Murine Leukocytes. Human PMNs were puri-
fied from blood obtained from healthy adult volunteers and
collected into acidified citrate. After addition of6% dextran 70
(McGaw, Irvine, CA), erythrocytes were allowed to sediment
for 1 hr at 25°C. The leukocyte-rich supernatant was overlaid
onto an equal volume of Ficoll/Paque (Pharmacia), and
centrifuged at 400 x g for 20 min. PMNs (>95% pure, the
difference were eosinophils) were recovered from the pellet
and washed in Ca2+/Mg2+ free Hanks' balanced salt solution
(HBSS). Residual erythrocytes were lysed with hypotonic
saline. Eosinophils (>80% pure, the difference were neutro-
phils) were obtained from a donor with idiopathic hypereosi-
nophilic syndrome using the same procedure. Synovial fluid
leukocytes were examined in samples of joint fluids submitted
to the clinical hematology laboratory. COX-1 and COX-2
genetically deficient mice were generated as described (27, 28).
Experiments were carried out with 8- to 12-week-old mice.
Macrophages from COX-1 and COX-2 genetically deficient
mice and wild-type littermates were obtained by lavaging the
peritoneal cavity with 5 ml of cold HBSS containing heparin
(10 units/ml).
Lipid Body Induction and Enumeration. Leukocytes (106
cells per ml) were incubated with concentrations of AA, OA,
or vehicle (0.1% ethanol) at 37°C in a 5% C0295% 02
atmosphere, and after 1 hr leukocytes (105 cells per slide) were
cytocentrifuged onto glass slides. For inhibitor studies, leuko-
cytes were pretreated for 1 hr with concentrations of inhibitors
or vehicle as indicated. Cell viability, determined by Trypan
blue dye exclusion at the end of each experiment, was always
greater than 90%. Stock solutions of A23187, indomethacin,
aspirin, sodium salicylate, piroxicam, and NS-398, prepared in
dimethyl sulfoxide (DMSO) and stored at -20°C, were diluted
in Ca2+/Mg2+-free HBSS to the indicated concentration im-
mediately before use. The final DMSO concentration was
always lower than 0.1% and had no effect on lipid body
numbers. Slides, while still moist, were fixed in 3.7% formal-
dehyde in Ca2+/Mg2+-free HBSS (pH 7.4), rinsed in 0.1 M
cacodylate buffer (pH 7.4), stained in 1.5% OS04 (30 min),
rinsed in H20, immersed in 1.0% thiocarbohydrazide (5 min),
rinsed in 0.1 M cacodylate buffer, restained in 1.5% OS04 (3
min), rinsed in H20, dried, and mounted. The morphology of
fixed cells was observed, and lipid bodies were enumerated
with phase contrast microscopy and a 10OX objective lens in
50 consecutively scanned leukocytes.
Prostaglandin (PG)E2, Leukotriene (LT)B4, and LTC4 As-
says. Leukocytes (106 cells per ml) were stimulated with
concentrations of AA, OA, or vehicle (0.1% ethanol) at 37°C
for 1 hr to induce lipid body formation; after which a sample
was taken for lipid body enumeration, and the cells were
washed in Ca2+/Mg2+-free HBSS. Leukocytes, resuspended in
1 ml of HBSS containing Ca2+/Mg2+, were stimulated with 0.5
AM A23187 at 37°C for 15 min. Reactions were stopped on ice,
and samples were centrifuged (800 x g for 10 min at 4°C). In
each replicate supernatant or extracted cell pellet, PGE2,
LTB4, and LTC4 were assayed in duplicate by ELISA (Cayman
Chemicals, Ann Arbor, MI).
AA Uptake. Neutrophils (106 per ml) were labeled with
14C-AA (0.2 ,uM) together with either vehicle, aspirin (10
,ug/ml), indomethacin (1 ,ug/ml), or sodium salicylate (10
,ug/ml) for 1 hr. After the incubation period, lipid body
formation was elicited by AA (15 ,uM). The cells were washed
three times in Ca2+/Mg2+-free HBSS and analysis of incor-
porated 14C-AA in the cell pellet was performed by liquid
scintillation counting.
Statistical Analysis. Results, expressed as mean ± SEM,
were analyzed by analysis of variance followed by the New-
man-Keuls Student's t test with the level of significance set at
P < 0.05. Correlation coefficients were determined by linear
regression, and correlation analysis was performed by Fisher's
r to z transformation with the level of significance set at P <
0.05.
RESULTS
Lipid Body Formation. Normal PMNs contain few lipid
bodies (Fig. 1A); but PMNs at sites of inflammatory reactions,
such as septic arthritis (Fig. 1B), contain markedly increased
numbers of lipid bodies. Common alcohol-based hematologic
stains cause dissolution of lipid bodies (Fig. 1D), which pre-
cludes their recognition. However, with appropriate lipid
fixation, increased lipid body numbers have been observed in
many types of leukocytes when these cells are involved in a
variety of infectious, allergic, neoplastic, and other inflamma-
tory diseases (15, 29). Normal PMNs can be stimulated with
cis-unsaturated, but not saturated, fatty acids, such as AA and
the non-eicosanoid precursor OA, to rapidly form (within 1 hr)







FIG. 1. Lipid bodies in human PMNs. Lipid bodies are sparse in
normal donor-derived blood PMNs (A) but very prominent in synovial
fluid PMNs from a patient with septic arthritis (B) and in normal
donor blood-derived PMNs after stimulation in vitro with 5 IIMAA for
1 hr at 37°C (C). Without prior lipid preservation, however, lipid
bodies are solubilized by routine staining and become undetectable
(D) in the same synovial fluid PMNs as in B. Murine peritoneal
macrophages contain few lipid bodies in resting conditions (E); but can
also be stimulated in vitro with 15 ,uMAA for 1 hr at 37°C to form lipid
bodies (F). Cytocentrifuged leukocytes were fixed in 3.7% formalde-
hyde in HBSS and stained with osmium tetroxide, (A-C, E, and F) or
were fixed in methanol and stained with Diff-Quik (Baxter, Miami,
FL) (D).
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FIG. 2. (A and B) Aspirin (ASA) and (C) other NSAIDs inhibit AA- and OA-induced lipid body formation in human PMNs (A and C) and
eosinophils (B). Lipid bodies/cell with vehicle alone (open bar), fatty acid stimulation (solid bar), fatty acids plus ASA pretreatment (striped bar)
(A and B), and NSAID inhibition with indomethacin (dotted bar), sodium salicylate (vertically striped bar), and piroxicam (cross-hatched bar) (C)
are indicated. Cells (106 per ml) were pretreated with aspirin (10 ,ug/ml), indomethacin (1 ,ug/ml), sodium salicylate (10 ,ug/ml), piroxicam (10
jig/ml), or vehicle (0.1% DMSO) for 1 hr, and then stimulated with 15 ,uM AA, 10 ,tM OA, or vehicle (0.1% ethanol) for 1 hr at 37°C. Values
are expressed as mean±SEM of 50 consecutively counted cells of one representative experiment from 3-5 independent assays. Statistically
significant differences (P < 0.05, Student's t test) between lipid bodies/cell with vehicle alone and fatty acid stimuli are noted by a triangle, and
between fatty acid stimuli alone and pretreatment with ASA or NSAID by *.
bodies formed in vivo (10, 15, 16). As with human cells, mouse
macrophages contain only few lipid bodies under normal
conditions (Fig. 1E) and can also be stimulated in vitro with
cis-unsaturated fatty acids to form lipid bodies (Fig. 1F).
Aspirin and NSAID Inhibition of Lipid Body Induction.
Since lipid body numbers increase during inflammatory pro-
cesses and might be related to the formation of eicosanoid
mediators of inflammation, we investigated aspirin's effects on
cis-fatty acid-induced lipid body formation. Aspirin inhibited
lipid body formation induced by both AA and OA in human
PMNs and eosinophils (Fig. 2A and B), as did the structurally
unrelated NSAIDs, indomethacin and piroxicam (Fig. 2C).
Moreover, sodium salicylate (which does not inhibit COX; see
refs. 19 and 25) was as potent as aspirin in inhibiting lipid body
formation elicited by both cis-fatty acids (Fig. 2C), suggesting
8 12 0 4 8 12
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that NSAID inhibition of lipid body formation was indepen-
dent of COX inhibition. Aspirin, indomethacin, and sodium
salicylate did not inhibit 14C-AA uptake by human PMNs
stimulated by AA (data not shown), indicating that these
agents were not acting by diminishing fatty acid uptake.
Aspirin Inhibition of Lipid Body Induction is COX Inde-
pendent. To determine the role of the two COX isoforms in
cis-fatty acid-induced lipid body formation, macrophages from
wild-type and COX-1- or COX-2-deficient mice (27, 28) were
studied. Both AA and OA induced lipid body formation with
no differences between wild type and either COX-1 or COX-2
deficient macrophages (Fig. 3 A and B), indicating that lipid
body formation is not dependent on COX-1 or COX-2 activity.
Aspirin, sodium salicylate, and indomethacin inhibited AA-
induced lipid body formation in macrophages from wild-type
wild-type (+/+) COX-1 (-/-) COX-2 (-/-)
FIG. 3. Aspirin and NSAIDs inhibit cis-fatty acid-induced-lipid body formation independent of COX. Peritoneal macrophages from wild type,
and COX-1 (A) and COX-2 (B) deficient mice responded similarly to stimulation with AA and OA and pretreatment with NSAIDs (C). InA and
B, AA and OA are represented by squares and circles, respectively; and solid and open symbols, respectively, represent wild-type and COX-deficient
mice. Macrophages (106 per ml) were incubated with AA and OA at varying concentrations for 1 hr. Values (mean ± SEM) calculated from 50
consecutive macrophages from four mice each counted blindly without knowledge of the genotypes of the mice. In C, for wild-type (+/+) and
COX-1- and COX-2-deficient (-/-) mice, pretreatment with aspirin (open bar), indomethacin (dotted bar), sodium salicylate (vertically striped
bar), or NS-398 (cross-hatched bar) each significantly suppressed lipid body induction compared with AA alone (P < 0.05, Student's t test).
Macrophages (106 per ml) were pretreated with aspirin (10 ,ug/ml), indomethacin (1 ,ug/ml), sodium salicylate (10 ,ug/ml), NS-398 (10 mM), or
vehicle (0.1% DMSO) for 1 hr, and then stimulated with 15 ,uM AA or vehicle (0.1% ethanol) for 1 hr. Values are expressed as the percent lipid
body numbers induced by 15 ,uM AA alone. (Values for unstimulated cells ranged from 2.8-4.7 lipid bodies/cell, whereas cells stimulated with
15 ,uM AA ranged from 8.6-9.1 lipid bodies/cell in different experiments.)
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FIG. 4. Cis-fatty acids induce both lipid body formation and enhanced eicosanoid generation. AA- and OA-induced lipid body formation (solid
bar) and priming (striped bar) for LTB4 (A), PGE2 (B) and LTC4 (C) production by human PMNs (A and B) and eosinophils (C). Cells (106 per
ml) were stimulated for 1 hr at 37°C with concentrations ofAA, OA, or vehicle (0.1% ethanol) alone. Data are mean ± SEM from 5-10 independent
assays (A and B) or from quadruplicates of a representative experiment (C). With each fatty acid and each cell type, increasing numbers of lipid
bodies correlated with increased production of each eicosanoid (r > 0.9, P < 0.05 for all, Fisher's r to z transformation). Asterisk indicates
significantly greater than value without fatty acid stimulation (P < 0.05, Student's t test). (D) The effect of 15 ,uM AA or vehicle (0.1% ethanol)
on lipid body formation (solid bar) and priming (striped bar) for PGE2 production was investigated in peritoneal macrophages from wild type and
COX-1 and COX-2 deficient mice. Data are mean ± SEM from 2-7 mice evaluated blindly without knowledge of the genotypes. Lipid bodies were
enumerated microscopically following osmium staining. LTB4, LTC4, and PGE2 in supernatants were measured by ELISA after incubation with
0.5 ,uM A23187 for 15 min.
and COX-1- and COX-2-deficient mice (Fig. 3C). Thus,
inhibition by these NSAIDs takes place even in the absence of
COX-1 or COX-2. Furthermore, NS-398, recognized as a
specific COX-2 inhibitor (30, 31), also inhibited lipid body
formation in wild-type, and COX-1- and even COX-2-deficient
macrophages (Fig. 3C). Overall, these results indicate that
NSAID inhibition of lipid body formation, including that with
the nominally specific COX-2 inhibitor, NS-398, are indepen-
dent of COX inhibition.
Induction of Enhanced Eicosanoid Generation. Since lipid
bodies are stores of the eicosanoid precursor AA (15, 16) and
contain eicosanoid-forming enzymes (12, 13, 14), we investi-
gated whether increased numbers of lipid bodies correlated
with enhanced generation of eicosanoids by PMNs and eosin-
ophils. Unstimulated leukocytes respond to specific receptor-
mediated agonists or submaximal concentrations of calcium
ionophore by generating low levels of eicosanoids. However, in
a process known as "priming," prior stimulation with various
agents, including cis-fatty acids, protein kinase C activators,
and PAF, renders cells capable of generating greater quantities
of eicosanoids (11, 32-36). After PMNs and eosinophils were
incubated with concentrations of AA or OA for 1 hr, lipid
bodies were enumerated and replicate leukocytes were stim-
ulated with 0.5 ,tM calcium ionophore. AA as well as OA
dose-dependently induced concordant increases in both lipid
body numbers and priming for enhanced LTB4 (Fig. 4A4), PGE2
(Fig. 4B), and LTC4 (Fig. 4C) production. Increased numbers
of AA- and OA-induced lipid bodies in both cell types
correlated with the increased quantities of each eicosanoid
generated by the primed leukocytes. Notably, stimulation of
leukocytes with OA, not itself an eicosanoid precursor fatty
acid, led to increments in the production of each eicosanoid
that quantitatively paralleled the incremental increases in lipid
body numbers (PGE2: r, 0.99, P < 0.01; LTB4: r, 0.99, P < 0.01;
LTC4: r, 0.95, P < 0.05). Thus, the capacity of two different
leukocyte types to generate greater quantities of COX and
lipoxygenase pathway-derived eicosanoids correlated with lev-
els of lipid bodies in these cells.
To determine which COX is responsible for enhanced
prostaglandin production, we evaluated the effects of COX-1
or COX-2 deficiency on priming. Primed COX-2-deficient
macrophages were found to be indistinguishable from wild-
type cells in both lipid body and PGE2 formation (Fig. 4D),
indicating that COX-2 does not have a role in PGE2 production
by primed macrophages. However, primed COX-1-deficient
macrophages demonstrated severely diminished levels of
PGE2 (Fig. 4D), identifying COX-1 as the enzyme responsible
for enhanced PGE2 production induced early in AA-treated
macrophages.
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FIG. 5. Aspirin and sodium salicylate inhibit cis-fatty acid-induced priming for enhanced leukotriene production. (A) LTB4 production by human
PMNs treated with vehicle control (open bars), cis-fatty acid (solid bars), or cis-fatty acid plus aspirin (striped bars), or sodium salicylate (vertically
striped bars). PMNs (106 per ml), pretreated with aspirin (10 jig/ml), sodium salicylate (10 ,ug/ml), or vehicle (0.1% DMSO) for 1 hr at 37°C, were
then stimulated with 5 ,uM AA, 10 ,uM OA, or vehicle (0.1% ethanol) for 1 hr. Data are mean ± SEM from four to eight independent assays
performed'in duplicate. (B) LTC4 production by human eosinophils treated with vehicle control (open bars), cis-fatty acid (solid bars), or cis-fatty
acid plus aspirin (striped bars). Eosinophils (106 per ml), pretreated with aspirin (10 ,ug/ml) or vehicle for 1 hr at 37°C, were then stimulated with
15 ,uM AA, 10 t.M OA or vehicle (0.1% ethanol) for 1 hr. Data are mean ± SEM from quadruplicates of a representative experiment. After
incubation with 0.5 ALM A23187 for 15 min, LTB4 and LTC4 in supernatants were measured by ELISA. Statistically significant differences (P <
0.05, Student's t test) between vehicle alone and fatty acids are represented by a triangle, and between fatty acids alone and with aspirin or sodium
salicylate pretreatment are indicated by *.
Aspirin Inhibition ofEnhanced Eicosanoid Generation. We
evaluated whether aspirin inhibition of lipid body formation
would affect cis-fatty acid-induced priming for enhanced pro-
duction of both COX- and lipoxygenase-derived eicosanoids.
Aspirin pretreatment inhibited PGE2 production by human
PMNs and eosinophils in either vehicle- or cis-fatty acid-
stimulated leukocytes (data not shown), but this inhibition
might be due solely to aspirin inhibition of COX. In contrast,
aspirin is devoid of direct inhibitory effects upon lipoxygenases
in leukocytes and platelets (37-39). We found that aspirin
significantly inhibited AA- and OA-induced priming for en-
hanced production of 5-lipoxygenase-derived LTB4 by PMNs
(Fig. SA) and LTC4 by eosinophils (Fig. 5B) and that sodium
salicylate likewise inhibited cis-fatty acid-induced priming for
enhanced LTB4 production by PMNs (Fig. 5A). Aspirin was
not acting to block pathways of AA mobilization or metabo-
lism activated by calcium ionophore, since aspirin failed to
inhibit calcium ionophore-induced LTB4 and LTC4 production
in cells not prestimulated with cis-fatty acids (Fig. 5), and was
not inhibiting eicosanoid export (no residual intracellular
eicosanoids were detectable). Aspirin's inhibition of priming
for enhanced eicosanoid production correlated with its ability
to inhibit cis-fatty acid-induced lipid body formation.
DISCUSSION
Our findings indicate that lipid bodies have roles in the
enhanced formation of eicosanoid mediators of inflammation.
Lipid bodies are specialized intracellular domains whose for-
mation in leukocytes is rapidly inducible within 1 hr by
cis-unsaturated fatty acids or by PAF (10, 11). The induction
of lipid body formation correlated with development of an
enhanced capacity for eicosanoid formation, a process termed
"priming." Interestingly, priming agents, including cis-fatty
acids, protein kinase C activators, and PAF, in the concentra-
tions and times previously recognized to effectively prime
PMNs for enhanced leukotriene production (11, 32, 33, 35, 36),
are identical with stimulatory agents and conditions necessary
to induce lipid body formation (10, 11). With bothAA and OA
stimulation, numbers of lipid bodies correlated with enhanced
levels of LTB4, LTC4, and PGE2 formed by human PMNs and
eosinophils (Fig. 3). Likewise, with PAF stimulation, numbers
of lipid bodies induced in PMNs correlated with enhanced
levels of lipoxygenase (LTB4)- and COX (PGE2)-derived
eicosanoids formed in response to submaximal calcium iono-
phore (11). Additional support for a relationship between lipid
body formation and heightened eicosanoid formation comes
from studies with inhibitors. In this study, aspirin and various
NSAIDs both inhibited cis-fatty acid-induced lipid body for-
mation and inhibited the enhanced formation of lipoxygenase
(LTB4, LTC4)- and COX (PGE2)-derived eicosanoids (Figs. 2,
3C, and 5). Inhibition of PAF-induced lipid body formation in
PMNs with the mRNA and protein synthesis inhibitors, acti-
nomycin D and cycloheximide, respectively, also inhibited
enhanced LTB4 and PGE2 formation (11). Thus, lipid body
formation may provide a cellular basis for "priming" that
augments eicosanoid generation.
Aspirin and NSAIDs inhibited cis-fatty acid-induced lipid
body formation. This inhibition was independent of inhibition
of either COX-1 or COX-2. AA- and OA-induced lipid body
induction in macrophages from COX-1- and COX-2-deficient
mice was not impaired; and NSAIDs, including aspirin, sodium
salicylate, indomethacin, and NS-398, inhibited AA-induced
lipid body formation equally in macrophages from wild-type
and COX-1- or COX-2-deficient mice (Fig. 3). Other evidence
also suggests COX-2 does not participate in lipid body forma-
tion. COX-2 induction takes 2-48 hr (1-4), whereas lipid body
formation occurs within 1 hr. Furthermore, dexamethasone, a
potent inhibitor of COX-2 expression (40), did not block lipid
body formation (data not shown). Thus, COX-2 is unlikely to
have a role in the induction of lipid bodies, and since this
induction can still occur in COX-1-deficient macrophages
neither COX is essential in this process.
Whereas stimulation of COX-2 formation is one inducible
mechanism to heighten eicosanoid synthesis, the induction of
lipid body formation constitutes another mechanism for en-
hancing the synthesis of eicosanoid mediators of inflamma-
tion. Lipid body induction develops more rapidly than COX-2
induction (1-4). Moreover, whereas COX-2 induction leads to
the enhanced generation of only COX-derived eicosanoids,
lipid body induction is associated with the enhanced formation
of both lipoxygenase- and COX-derived eicosanoids. The
enhanced COX-derived eicosanoids associated with lipid body
induction are likely COX-1 derived since enhanced PGE2
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generation was deficient in COX-1-, but not COX-2-, deficient
macrophages (Fig. 4D). These findings indicate that COX-1,
and not solely induced COX-2, may have a significant role in
inflammatory processes, a possibility supported by previous
data demonstrating diminished AA-induced inflammation in
COX-1-deficient mice (27,28). Finally, of special pertinence to
understanding the antiinflammatory activities of aspirin, as-
pirin and NSAIDs, by a COX-independent mechanism, inhibit
the early induction by cis-fatty acids of both lipid body
formation and priming for enhanced eicosanoid formation in
leukocytes. This action of aspirin and related NSAIDs extends
their antiinflammatory capacity to include suppression of
more than COX pathway-derived eicosanoids and indicates
that inhibition of induction of lipid body formation may
constitute a novel target for antiinflammatory therapies.
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